Towards development of stable formulations of a live attenuated bacterial vaccine: A preformulation study facilitated by a biophysical approach

Human Vaccines

Volumn 5, Issue 5, 2009, Pages 322-331

  Zeng, Yuhong ^a   Fan, Haihong ^a   Chiueh, Gary ^b   Pham, Binh ^b   Martin, Russ ^b   Lechuga Ballesteros, David ^b   Truong, Vu L ^b   Joshi, Sangeeta B ^a   Middaugh, C Russell ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b Aridis Pharmaceuticals   (United States)

Author keywords

Circular dichroism spectroscopy; Empirical phase diagram; Excipient screening; Fluorescence spectroscopy; Foam drying; Live attenuated bacterial vaccine

Indexed keywords

GLUTAMIC ACID; LIVE VACCINE; STABILIZING AGENT; SUCROSE; TREHALOSE; TYPHOID VACCINE;

ARTICLE; CELL MEMBRANE FLUIDITY; CELL VIABILITY; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; FLUORESCENCE; HIGH THROUGHPUT SCREENING; NONHUMAN; PH; PHYSICAL PHASE; PREFORMULATION; SALMONELLA TYPHI; SPECTROSCOPY; TEMPERATURE SENSITIVITY; TRANSITION TEMPERATURE;

CIRCULAR DICHROISM; DRUG STABILITY; EXCIPIENTS; GLUTAMIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; MICROBIAL VIABILITY; POLYSACCHARIDES, BACTERIAL; SPECTRUM ANALYSIS; SUCROSE; TEMPERATURE; TYPHOID-PARATYPHOID VACCINES; VACCINES, ATTENUATED;

EID: 70349528139     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.5.7559     Document Type: Article

References (42)

1. Ebensen T, Link C, Guzman CA. Clasical bacterial vaccines. In: Kaufmann SHE, ed. Novel vaccination strategies. Wiley-VCH Verlag GmbH & Co 2004.
2. Loessner H, Endmann A, Leschner S, Bauer H, Zelmer A, zur Lage S, et al. Improving live attenuated bacterial carriers for vaccination and therapy. Int J Med Microbiol 2008; 298:21-6.
3. Corbel MJ. Reasons for instability of bacterial vaccines. Dev Biol Stand 1996; 87:113-24.
4. Germanier R, Furer E. Isolation and characterization of Gal E mutant Ty21a of Salmonella typhi: A candidate strain for a live, oral typhoid vaccine. J Infect Dis 1975; 131:553-8.
5. Black R, Levine MM, Young C, Rooney J, Levine S, Clements ML, et al. Immunogenicity of Ty21a attenuated Salmonella typhi given with sodium bicarbonate or in enteric-coated capsules. Dev Biol Stand 1983; 53:9-14.
6. Wahdan MH, Serie C, Germanier R, Lackany A, Cerisier Y, Guerin N, et al. A controlled field trial of liver oral typhoid vaccine Ty21a. Bull World Health Organ 1980; 58:469-74.
7. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987; 1:1049-52.
8. Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999; 17:22-7.
9. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 1990; 336:891-4.
10. Caron GN, Stephens P, Badley RA. Assessment of bacterial viability status by flow cytometry and single cell sorting. J Appl Microbiol 1998; 84:988-98.
11. Lehtinen J, Virta M, Lilius EM. Fluoro-luminometric real-time measurement of bacterial viability and killing. J Microbiol Methods 2003; 55:173-86.
12. Berney M, Hammes F, Bosshard F, Weilenmann HU, Egli T. Assessment and interpretation of bacterial viability by using the LIVE/DEAD BacLight Kit in combination with flow cytometry. Appl Environ Microbiol 2007; 73:3283-90.
13. Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF case study. J Pharm Sci 2003; 92:1805-20.
14. The Handbook - A Guide to Fluorescent Probes and Labeling Technologies. Invitrogen Molecular Probes: Invitrogen Molecular Probes.
15. Szollosi J. Fluidity/viscosity of biological membranes. In: Damjanovich S, Edidin M, Szollosi J, Tron L, eds. Mobility Proximity Biol Membr. Boca Raton: CRC 1994; 137-208.
16. Parasassi T, Krasnowska EK, Bagatolli L, Gratton E. Laurdan and Prodan as polarity-sensitive fluorescent membrane probes. J Fluoresc 1998; 8:365-73.
17. De Vequi-Suplicy CC, Benatti CR, Lamy MT. Laurdan in fluid bilayers: Position and structural sensitivity. J Fluoresc 2006; 16:431-9.
18. Nonoyama A, Laurence JS, Garriques L, Qi H, Le T, Middaugh CR. A biophysical characterization of the peptide drug pramlintide (AC137) using empirical phase diagrams. J Pharm Sci 2008; 97:2552-67.
19. Ausar SF, Foubert TR, Hudson MH, Vedvick TS, Middaugh CR. Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature. J Biol Chem 2006; 281:19478-88.
20. Ausar SF, Rexroad J, Frolov VG, Look JL, Konar N, Middaugh CR. Analysis of the thermal and pH stability of human respiratory syncytial virus. Mol Pharm 2005; 2:491-9.
21. Ruponen M, Braun CS, Middaugh CR. Biophysical characterization of polymeric and liposomal gene delivery systems using empirical phase diagrams. J Pharm Sci 2006; 95:2101-14.
22. Wilson WW, Wade MM, Holman SC, Champlin FR. Status of methods for assessing bacterial cell surface charge properties based on zeta potential measurements. J Microbiol Methods 2001; 43:153-64.
23. Alakomi HL, Skytta E, Saarela M, Mattila-Sandholm T, Latva-Kala K, Helander IM. Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. Appl Environ Microbiol 2000; 66:2001-5.
24. Lechuga-Ballesteros D, Miller DP, Zhang J. Residual water in amorphous solids, measurement and effects on stability. In: Levine H, ed. Amorphous Food and Pharmaceutical System. London: The Royal Society of Chemistry 2002; 275-316.
25. Ericsson M, Hanstorp D, Hagberg P, Enger J, Nystrom T. Sorting out bacterial viability with optical tweezers. J Bacteriol 2000; 182:5551-5.
26. Zhang T, Fang HH. Quantification of Saccharomyces cerevisiae viability using BacLight. Biotechnol Lett 2004; 26:989-92.
27. Biggerstaff JP, Le Puil M, Weidow BL, Prater J, Glass K, Radosevich M, et al. New methodology for viability testing in environmental samples. Mol Cell Probes 2006; 20:141-6.
28. Roszak DB, Colwell RR. Survival strategies of bacteria in the natural environment. Microbiol Rev 1987; 51:365-79.
29. Live/Dead BacLight Bacterial Viability Kits. Invitrogen Molecular Probes.
30. Zhou Y, Raphael RM. Solution pH alters mechanical and electrical properties of phosphatidylcholine membranes: relation between interfacial electrostatics, intramembrane potential and bending elasticity. Biophys J 2007; 92:2451-62.
31. Jiang G, Joshi SB, Peek LJ, Brandau DT, Huang J, Ferriter MS, et al. Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci 2006; 95:80-96.
32. Rexroad J, Martin TT, McNeilly D, Godwin S, Middaugh CR. Thermal stability of adenovirus type 2 as a function of pH. J Pharm Sci 2006; 95:1469-79.
33. Kissmann J, Ausar SF, Rudolph A, Braun C, Cape SP, Sievers RE, et al. Stabilization of measles virus for vaccine formulation. Hum Vaccin 2008; 4:350-9.
34. Lyophilization of biopharmaceuticals. In: Costantino HR, Pikal MJ, eds. Biotechnology: Pharmaceutical aspects. vol. 2. Arlington, VA: AAPS press 2004.
35. Maa YF, Prestrelski SJ. Biopharmaceutical powders: Particle formation and formulation considerations. Curr Pharm Biotechnol 2000; 1:283-302.
36. Lee G. Spray-drying of proteins. Pharm Biotechnol 2002; 13:135-58.
37. Truong-Le V. (Medimmune Vaccines, Inc., USA). Preservation of bioactive materials by freeze dried foam. 2003; Application: WO. p.72.
38. Jovanovic N, Bouchard A, Hofland GW, Witkamp GJ, Crommelin DJ, Jiskoot W. Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm Res 2004; 21:1955-69.
39. Annear DI. Recoveries of bacteria after drying in vacuo at a bath temperature of 100 degrees C. Nature 1966; 211:761.
40. Annear DI. Recoveries of bacteria after drying and heating in glutamate foams. J Hyg (Lond) 1970; 68:457-9.
41. Abdul-Fattah AM, Truong-Le V, Yee L, Nguyen L, Kalonia DS, Cicerone MT, et al. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): stability of a monoclonal antibody. J Pharm Sci 2007; 96:1983-2008.
42. Abdul-Fattah AM, Truong-Le V, Yee L, Pan E, Ao Y, Kalonia DS, et al. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: Stability of a vaccine. Pharm Res 2007; 24:715-27.